CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014

     CytoSorbents to Sponsor CytoSorb® Research Symposium at ISICEM 2014  PR Newswire  MONMOUTH JUNCTION, N.J., March 13, 2014  MONMOUTH JUNCTION, N.J., March 13, 2014 /PRNewswire/ --CytoSorbents Corporation (OTCQB: CTSO), a critical care immunotherapy company using blood purification to treat life-threatening illnesses in the intensive care unit, announced that it will sponsor a research symposium entitled:  "SIRS and SEPSIS – New Therapy with CytoSorb®"  at the 34^th International Symposium on Intensive Care and Emergency Medicine (ISICEM 2014) in Brussels, Belgium next week. The program is scheduled for Wednesday, March 19, 2014 from 6:15 – 7:45 PM in the ARC room of the Square – Brussels Meeting Center. Refreshments will be served.  Distinguished physicians will discuss the application of CytoSorb® extracorporeal cytokine reduction in sepsis and other inflammatory conditions, such as cardiac surgery.    oDr. Herwig Gerlach (Berlin, Germany): "Overshooting the inflammatory     response – The Root of all Evil?"   oDr. John Kellum (Pittsburgh, USA): Blood purification in SIRS and Sepsis:     A new paradigm"   oDr. Michael Quintel (Gottingen, Germany): Clinical Experience: Severe     sepsis/ septic shock and CytoSorb® therapy   oDr. Karl Trager (Ulm, Germany): Clinical Experience: Post-Cardiopulmonary     Bypass SIRS and CytoSorb® therapy.  In addition, attendees can visit CytoSorbents' exhibit booth in the Silver Foyer, Booth S.01 from March 18-21, 2014 to learn more about CytoSorb® immunotherapy for critical illnesses and how, through cytokine reduction, it targets a reduction of the potentially deadly systemic inflammatory response syndrome (SIRS) in order to prevent or treat organ failure and improve clinical outcomes.  About ISICEM  The International Symposium on Intensive Care and Emergency Medicine is organized by the Departments of Intensive Care and Emergency Medicine of Erasme University Hospital, Universite Libre de Bruxelles, in association with the Belgian Society of Intensive Care and Emergency Medicine. This annual conference was started in 1980 and has become established as one of the largest in its field, now attracting more than 6,000 participants from countries worldwide. The objectives of this four-day symposium are to provide participants with an up-to-date review of the most recent, clinically relevant, developments in research, therapy, and management of the critically ill. The meeting is open to all physicians, nurses, and other health professionals with an interest in critical care or emergency medicine.  About CytoSorbents   CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to modulate inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union as a safe and effective extracorporeal cytokine filter, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/  Forward-Looking Statements  This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release are not promises or guarantees and are subject to risks and uncertainties that could cause our actual results to differ materially from those anticipated. These statements are based on management's current expectations and assumptions and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements. Actual results may differ materially from those expressed or implied by the statements herein. Risk factors are detailed in the Company's Form 10-K filed with the SEC on April 3, 2013, which is available at http://www.sec.gov.  Please Click to Follow us on Facebook and Twitter  SOURCE CytoSorbents Corporation  Website: http://www.cytosorbents.com Contact: Company Contact: Dr. Phillip Chan, MD, PhD, Chief Executive Officer, CytoSorbents Corporation, (732) 329-8885 ext. *823, pchan@cytosorbents.com; or Investor Contact: Amy Vogel, CytoSorbents Corporation, (732) 329-8885 ext. *825, avogel@cytosorbents.com